baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ATOS/ FR0000051732 /

- -	Chg. -	Volume	Bid03:01:04	Ask03:01:04	Market Capitalization	Dividend Y.	P/E Ratio
2.065EUR	-	- Turnover: -	-Bid Size: -	-Ask Size: -	230.12 mill.EUR	-	-

GlobeNewswire 16/05 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats

GlobeNewswire 15/05 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...

GlobeNewswire 15/05 Calian Reports Record Results for the Second Quarter

GlobeNewswire 13/05 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 13/05 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing

GlobeNewswire 07/05 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 15/04 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...

GlobeNewswire 11/04 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

GlobeNewswire 09/04 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...

GlobeNewswire 01/04 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 27/03 Calian Announces the Appointment of New President of Advanced Technologies

GlobeNewswire 25/03 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

GlobeNewswire 19/03 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...

GlobeNewswire 18/03 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

GlobeNewswire 12/03 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...

GlobeNewswire 06/03 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...

GlobeNewswire 22/02 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

GlobeNewswire 16/01 New report reveals that 94% of global organizations have experienced email security incidents last y...

GlobeNewswire 09/01 Atossa Therapeutics Issues Letter to Shareholders

TeleTrader 03/01 Europe opens mixed with data, business in focus

TeleTrader 03/01 Airbus to purchase Atos' cyber security unit for $1.9B

GlobeNewswire 13/12/2023 Sodexo announces the composition of Pluxee’s future Board of Directors

GlobeNewswire 04/12/2023 Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

GlobeNewswire 20/11/2023 Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

ATOS/ FR0000051732 /

If you wish to receive reply to your feedback, please provide your email address.